101 results
In this study we aim to evaluate the effectivity of the current, standard treatment of uncomplicated urinary tract infections with fosfomycin, based on urine concentrations of fosfomycin in urine in healthy volunteers after receiving a single, oral…
Step 1 Primary objective: To describe the population pharmacokinetics of flucloxacillin for non-critically ill patients and determine the influence of covariates (demographics and renal function) on the kinetics of flucloxacillin. Step 2Primary…
Development and prospective validation of a pharmacokinetic model of flucloxacillin for dosing in patients with impaired renal function.
The purpose of the study is to investigate how quickly and to what extent RO7033877 and CMS are getting into your blood stream and how long your body takes to get rid of it (this is called pharmacokinetics) when they are given alone or given at the…
The main objective is to assess target attainment of cefotaxime levels in the critically ill treated with either continuously or intermittently dosed cefotaxime. Secondary objectives are: to develop a predictive mathematical pharmacokinetic (PK)…
To identify and clone antibodies that can neutralize the bacterial pathogens Escherichia coli and Pseudomonas aeruginosa.
The hypothesis is that a switch from intravenous to oral antimicrobial therapy is non-inferior to standard intravenous therapy in patients with low-risk SAB. Therefore, the primary objective of the trial is to demonstrate, that oral switch therapy (…
The purpose of this study is to provide insight in to what extent clinically significant systemic absorption of tobramycin occurs (resulting in a serum tobramycin concentration> 1.0 mg / L) in ICU and Medium Care ICU patients who are being…
The aim of this study is to describe the utility of beta-lactam and fluoroquinolone TDM programs in tertiary ICUs. Therefore, the main objective is to document whether empirical antibiotic dosing regimens of these antibiotics achieve defined…
The purpose of this study is to evaluate the efficacy of two antibiotics ( neomycin sulfate and colistin sulfate), followed by fecal bacteria therapy , to multidrug - resistant bacteria (E - ESBL and EPC) to be eradicated from the intestine.
Primary Objectives: To evaluate whether early, pre-hospital administration of antibiotics reduces 28-day mortality in patients referred to the ED with suspected severe sepsis or septic shock.Secondary Objective(s): 1. To compare whether there is a…
To investigate whether the current dosing regimen of ciprofloxacin, recommended by the Dutch *Stichting Werkgroep Antibioticabeleid* (SWAB) and applied at the Academic Medical Center for patients with various degrees of renal function admitted at…
To determine the effectiveness and, subsequently, the cost-effectiveness of a endoscopic transluminal step-up approach (ETD & ETN) versus a surgical step-up approach (PCD & VARD ,if not possible laparotomy) to improve clinical…
Primary objective: To determine the safety of once daily inhalation of the recommended daily dose of tobramycin with the Akita® and the PARI-LC® Plus nebulizer in patients with CF. Systemic absorption can be used as surrogate parameter for safety.…
Primairy objectivesTo study the pharmacokinetics (plasma and cerebrospinal fluid) of meropenem in infants <= 90 days of postnatal age with probable or confirmed bacterial meningitis (BM); To describe the safety profile of meropenem in the…
Primary objective: To investigate whether pharmacokinetics of the recommended dose of inhaled tobramycin, defined as serum tobramycin Area Under the Curve (AUC0-24hr), with the I-neb (75 mg) is equivalent to the PariLCPlus (300 mg) nebuliser in…
To assess piperacillin concentrations during continuous dosing of P/T in critically ill patients; to determine PK variables, e.g. creatinine clearance, leading to a predictive mathematical model enabling TDM and ideally establishing better a priori…
The first objective to investigate is the pharmacokinetics of DP tobramycin using the Cyclops® at four different dosages. The other objective is the local tolerability of DP tobramycin using the Cyclops® at four different dosages.
To determine the number of therapeutic first trough levels (vancomycin serum concentrations between 10 and 15 mg/L), when receiving a starting dose of 90 mg/kg/day. Furthermore, the number of subtherapeutic (serum concentration < 10 mg/L) and…
To determine the efficiency, safety and health care costs of a strategy using routine nebulisation of mucolytics and bronchodilators four times daily, with a strategy of nebulisation on a strict clinical indication only, in mechanical ventilated…